MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Levodopa(L-dopa)"

  • 2017 International Congress

    Combined Surgical Therapies for Optimal Management of Advanced Parkinson’s Disease

    L. Kirkpatrick, Y. Torres-Yaghi, A. Keys, N. Starr, T. Kimbason, C. Moussa, F. Amjad, F. Pagan (Washington, DC, USA)

    Objective: We report a case of a patient with advanced PD who began LCIG for refractory motor fluctuations while continuing longstanding STN-DBS. Background: LCIG and…
  • 2017 International Congress

    Specific Bdnf variants are associated with suboptimal response to levodopa but not to other dopaminergic medications or deep brain stimulation in Parkinson’s disease

    C. Sortwell, P. Auinger, J. Goudreau, B. Pickut, B. Berryhill, M. Hacker, D. [email protected], J. Lipton, A. Cole-Strauss, J. Elm, D. Fischer (Grand Rapids, MI, USA)

    Objective: We examined the impact of rs6265 and other brain-derived neurotrophic factor (Bdnf) variants in two subject cohorts: 1) early-stage Parkinson’s disease (PD) subjects from…
  • 2017 International Congress

    Improvement in attention/memory domains in advanced Parkinson’s disease patients treated with levodopa-carbidopa intestinal gel is associated with better quality of life

    D. Standaert, R. Rodriguez, J. Slevin, M. Lobatz, C. Hall, M. Facheris, J. Benesh, S. Dubow (Birmingham, AL, USA)

    Objective: To evaluate the relationship between non-motor symptom (NMS) severity, quality of life (QoL), and activities of daily living (ADL) in advanced Parkinson’s disease (PD)…
  • 2017 International Congress

    Effects of the administration of levodopa on postural control under visual tasks

    C. Bonnet, A. Delval, L. Defebvre (Lille, France)

    Objective: We tested if the administration of levodopa leads the patients with Parkinson’s disease to sway significantly more than the controls, especially under challenging visual…
  • 2017 International Congress

    Medication optimization in Parkinson’s disease patients with ON-state freezing using objective gait assessments

    T. Virmani (Little Rock, AR, USA)

    Objective: To determine whether objective gait assessments could guide therapeutic decision making in Parkinson’s disease (PD) patients reporting freezing of gait (FOG) in the levodopa-ON…
  • 2017 International Congress

    Safety of levodopa-carbidopa intestinal gel treatment in advanced Parkinson’s disease patients receiving ≥ 2000 mg daily dose of levodopa

    C. Zadikoff, J. Boyd, S. Dubow, L. Bergmann, W. Robieson, H. Ijacu, J. Benesh (Chicago, IL, USA)

    Objective: To examine the safety of levodopa-carbidopa intestinal gel treatment (LCIG, carbidopa-levodopa enteral suspension in the US) in advanced Parkinson’s disease (PD) patients that received…
  • 2017 International Congress

    Off-Target Implications of Nurr1 Agonist Therapy in Parkinson’s disease

    K. Steece-Collier, T. Collier, J. Stancati, C. Kemp, B. Daley, C. Sortwell (Grand Rapids, MI, USA)

    Objective: To examine the impact of Nurr1 agonists on regulation of striatal Nurr1 and levodopa (LD)-induced dyskinesias (LIDs) in a rat model of Parkinson’s disease…
  • 2017 International Congress

    Factors associated with occurrence of motor complications among Parkinson’s disease patients with levodopa treatment in Estonia

    L. Kadastik-Eerme, N. Taba, T. Asser, P. Taba (Tartu, Estonia)

    Objective: To identify the factors associated with the occurrence of motor complications among patients with Parkinson’s disease (PD) who receive levodopa treatment. Background:  Levodopa is the…
  • 2017 International Congress

    A long-term study on effectiveness of levodopa-carbidopa intestinal gel treatment in advanced Parkinson’s disease patients

    K.R. Chaudhuri, A. Antonini, W. Poewe, D. Standaert, P. Odin, J. Zamudio, L. Bergmann (London, United Kingdom)

    Objective: To present the design of and baseline patient characteristics from an ongoing global study assessing the long-term effectiveness of levodopa-carbidopa intestinal gel (LCIG, carbidopa-levodopa…
  • 2017 International Congress

    An Unusual Cause of Rhabdomyolysis in Parkinson’s disease

    Y. Pitakpatapee, C. Satukijchai, P. Srivanitchapoom (Bangkok, Thailand)

    Objective: To describe an unusual cause of rhabdomyolysis in patient with advanced Parkinson’s disease (PD) treated with levodopa. Background: Rhabdomyolysis is a serious and life-threatening…
  • « Previous Page
  • 1
  • …
  • 46
  • 47
  • 48
  • 49
  • 50
  • …
  • 57
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • An atypical and interesting feature of Parkinson´s disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • #23812 (not found)
  • Approaching Health Care Shaped by Generational Expectations (The AGE Study): Generational Perspective Related to Time
  • Application of the “5-2-1” Screening Criteria in Advanced Parkinson’s Disease Patients Treated with Levodopa-Carbidopa Intestinal Gel: Interim Analysis from the DUOGLOBE Study
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Effect of Ketone Ester Supplementation on Motor and Non-Motor symptoms in Parkinson's Disease
  • An atypical and interesting feature of Parkinson´s disease
  • Patients with Essential Tremor Live Longer than their Relatives
  • DaTscan in clinical evaluation of Multiple System Atrophy
  • Decision-making process for opicapone’s bedtime regimen
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley